The Impact of Vaping Ethanol in the Evaluation of Impairment

Sponsor
Virginia Commonwealth University (Other)
Overall Status
Completed
CT.gov ID
NCT03826303
Collaborator
U.S. Department of Justice (U.S. Fed)
17
1
4
12.2
1.4

Study Details

Study Description

Brief Summary

The purpose of this research study is to find out about ethanol-containing e-cigarettes impact ethanol breath tests, field sobriety tests, or other tests of sobriety. Ethanol is a common part of e-cigarette liquids.

Condition or Disease Intervention/Treatment Phase
  • Other: E-cigarette liquid with ethanol, 1 puff
  • Other: E-cigarette liquid without ethanol, 1 puff
  • Other: E-cigarette liquid with ethanol, 10 puffs
  • Other: E-cigarette liquid without ethanol, 10 puffs
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
17 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
The Impact of Vaping Ethanol in the Evaluation of Impairment
Actual Study Start Date :
Apr 2, 2021
Actual Primary Completion Date :
Apr 8, 2022
Actual Study Completion Date :
Apr 8, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: E-cigarette with ethanol, 1 puff

Other: E-cigarette liquid with ethanol, 1 puff
E-cigarette liquid with ethanol, 1 puff

Placebo Comparator: E-cigarette without ethanol, 1 puff

Other: E-cigarette liquid without ethanol, 1 puff
E-cigarette liquid without ethanol, 1 puff

Experimental: E-cigarette with ethanol, 10 puffs

Other: E-cigarette liquid with ethanol, 10 puffs
E-cigarette liquid with ethanol, 10 puffs

Placebo Comparator: E-cigarette without ethanol, 10 puffs

Other: E-cigarette liquid without ethanol, 10 puffs
E-cigarette liquid without ethanol, 10 puffs

Outcome Measures

Primary Outcome Measures

  1. Preliminary breath test for ethanol [Conducted before and after the e-cigarette is used by the participant, at multiple time points (change from baseline reading at 27, 35, 40, 45, and 56 minutes after e-cigarette use)]

    Initial type of breath test used (gives percent blood alcohol concentration)

  2. Evidentiary breath test for ethanol [Conducted before and after the e-cigarette is used by the participant, at multiple time points (change from baseline at 29, 37, 42, 47, and 58 minutes after e-cigarette use)]

    Secondary type of breath test used (gives percent blood alcohol concentration)

  3. Standard Field Sobriety Test [Conducted before and after the e-cigarette is used by the participant, at multiple time points (change from baseline at 30 and 49 minutes after e-cigarette use)]

    Test used to determine sobriety

Other Outcome Measures

  1. Direct Effects of Vaping Questionnaire [Administered after e-cigarette use (at 39 minutes after e-cigarette use)]

    Questionnaire that asks participants about their vaping experience (10 questions, each scored from 0 - 100)

  2. Biphasic Alcohol Effects Scale [Conducted before and after the e-cigarette is used by the participant (change from baseline at 39 and 54 minutes after e-cigarette use)]

    Questionnaire that asks participants about effects associated with alcohol use (14 questions, each scored from 0 - 10)

  3. General Labeled Magnitude Scale [Administered after e-cigarette use (at 39 minutes after e-cigarette use)]

    Questionnaire that asks participants about flavor sensation, harshness/irritancy, and "throat hit" of the e-cigarette (3 questions, each scored from 0 - 100)

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Individuals must be e-cigarette users who are 21-65, willing to provide informed consent, attend the lab sessions as needed. Participants must agree to use designated products according to study protocol.
Exclusion Criteria:
  • Women will be excluded if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.

  • Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Virginia Commonwealth University Richmond Virginia United States 23298

Sponsors and Collaborators

  • Virginia Commonwealth University
  • U.S. Department of Justice

Investigators

  • Principal Investigator: Alison Breland, PhD, Virginia Commonwealth University

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT03826303
Other Study ID Numbers:
  • HM20015064
  • 2018-75-CX-0036
First Posted:
Feb 1, 2019
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022